SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study
Nicola Maurea(Cancer Institute (WIA)), Vincenzo Quagliariello(Cancer Institute (WIA)), Vincenzo Giordano(University of Alabama at Birmingham), Flávia Martão Flório(Faculdade São Leopoldo Mandic), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Renato Franco(Istituto di Chimica Biomolecolare), Isabella Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Séréna Grimaldi(Université Paris-Saclay), Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marco Montella(University of Campania "Luigi Vanvitelli"), Marino Scherillo, Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), F M Zito(University of Campania "Luigi Vanvitelli"), Giuseppe Palma(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 2
Related Papers
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
|The Lancet. Gastroenterology & hepatology|2020|602
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108